Source: Google NewsPublished on 2021-02-22
Related Articles:
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
- Global Parkinson's Disease Drug Market Top Key Players- Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Kyowa Hakko Kirin Pharma, Astellas Pharma, Desitin Arzneimittel, Endo Pharmaceuticals - Financial Newspaper September 9, 2019 Global Parkinson's Disease Drug Market Top Key Players- Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Kyowa Hakko Kirin Pharma, Astellas Pharma, Desitin Arzneimittel, Endo Pharmaceuticals Financial NewspaperParkinson's Disease Drug. Global Parkinson's Disease Drug market size will increase to xx Million US$ by 2025, from xx Million US$ in 2018, at a CAGR of xx% ...
- 2021: Wish list January 26, 2021 # # # # Here at the Science of Parkinson’s, we don’t like making predictions – that’s a fool’s game. We would rather focus our attention on interesting ideas and trends, discussing what we hope to see happen in the future, and exploring different ways and means by which change could occur. It is done in the hope that someone…
- Being ly-mphatic about drainage issues February 4, 2021 # # # # The lymphatic network is an important part of our body’s defense system. It is made up of an enormous web of vessels and nodes which help to protect us from infection and disease. This network transports a colourless fluid (called lymph), which serves two primary functions: 1.) it contains infection-fighting white blood cells that help in…
- The basket case February 10, 2021 # # # # One of the more interesting pieces of clinical trial news in 2020 was the publication of the results of a “basket study” for neurological conditions. This was a trial that involved a drug being tested on a selection of neurodegenerative conditions, rather than just one condition. Between December 2013 to May 2017, researchers recruited a total…
- Trying to LIMP-2 the lysosome February 8, 2021 # # # # Lysosomes are small bags of enzymes that are used to break down material inside of cells – digesting newly absorbed food or recycling old/used proteins and rubbish. Recently researchers have been discovering increasing evidence that points towards dysfunction in lysosomes as a key influential player in neurodegenerative conditions, like Parkinson’s. There are several Parkinson’s genetic risk…
- Parkinson's Disease Drug Market 2019 Healthcare Analysis, Clinical Reviews and Therapeutics Assessment – Abbvie, Kyowa Hakko Kirin Pharma, Astellas Pharma, Desitin Arzneimittel - SocioHerald August 28, 2019 Parkinson's Disease Drug Market 2019 Healthcare Analysis, Clinical Reviews and Therapeutics Assessment – Abbvie, Kyowa Hakko Kirin Pharma, Astellas Pharma, Desitin Arzneimittel SocioHeraldThe Global Parkinson's Disease Drug Market Research Report Forecast 2019-2025: The research study has been prepared with the use of in-depth qualitative ...
- Driving Under the Influence of Parkinson’s May 6, 2017 “Have you ever noticed that anybody driving slower than you is an idiot, and anyone going faster than you is a maniac?” George Carlin “If all the cars in the United States were placed end to end, it would probably be Labor Day Weekend.” Doug Larson The Dilemma: At some age in our life, maybe, just maybe, we could lose…
- Monthly Research Review – November 2020 November 30, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- 2019: Year in review December 31, 2019 In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
- Parkinson’s: Reflective Gratitude of Life December 20, 2019 “We don’t need more to be thankful for, we just need to be more thankful.” Carlos Castaneda “Take as a gift whatever the day brings forth.” Horace Introduction: The title of this blog post says it all. At the age of 66 years old, I stand before you thinking I need to be more thankful. Really? Yes, many deserve my gratitude…
- Parkinson’s: Reflective Gratitude of Life December 20, 2019 “We don’t need more to be thankful for, we just need to be more thankful.” Carlos Castaneda “Take as a gift whatever the day brings forth.” Horace Introduction: The title of this blog post says it all. At the age of 66 years old, I stand before you thinking I need to be more thankful. Really? Yes, many deserve my gratitude…
- Kyowa Hakko Kirin tries a second time with Parkinson's med istradefylline - Seeking Alpha April 4, 2019 Kyowa Hakko Kirin tries a second time with Parkinson's med istradefylline Seeking AlphaThe FDA accepts for review Kyowa Hakko Kirin Co., Ltd.'s (KYKOF) resubmitted marketing application seeking approval for istradefylline, a selective adenosi.
- Monthly research review – October 2019 October 31, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Global Parkinson's Disease Drug Market Overview 2019: Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical - Thefeedgraph May 28, 2019 Global Parkinson's Disease Drug Market Overview 2019: Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical ThefeedgraphHome · Global Parkinson's Disease Drug Market Overview 2019: Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical · May 28, 2019 Zion ...
- In-Depth Comprehensive Study on Parkinson's Disease Drug Market Forecast to 2024 with Focusing on Eminent Players- Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie - Market Report Gazette September 10, 2019 In-Depth Comprehensive Study on Parkinson's Disease Drug Market Forecast to 2024 with Focusing on Eminent Players- Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie Market Report GazetteMarket Report Gazette provides latest industry trending news, news *service*, IT & Technology news helps businesses connect with their target audiences in ...
- Kyowa Hakko up 3% on Nourianz Parkinson's approval - The Pharma Letter August 28, 2019 Kyowa Hakko up 3% on Nourianz Parkinson's approval The Pharma LetterShares in Kyowa Hakko Kirin closed 3% up on Wednesday with news of the US Food and Drug Administration's (FDA) approval of Nourianz (istradefylline) ...
- Here's How Parkinson's disease Drugs Market 2019 | Strategic Assessment by Top Players GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Merck, Akorn - Health Gazette August 24, 2019 Here's How Parkinson's disease Drugs Market 2019 | Strategic Assessment by Top Players GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Merck, Akorn Health GazetteOverview: Parkinson's disease is one of the most prevalent neurodegenerative disorders, which progresses with age because of damaged dopaminergic cells in ...